NCT04873258Recruiting
Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease
Development of a Non-invasive Screening Tool to Predict Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Volunteers on Clinical Trials Utilising Machine-learning and Bioimpedance Vector Analysis
Source: ClinicalTrials.gov · Last updated 19 Aug 2026
Brief summary (registry, in English)
A generic screening study to establish structural and/or functional baselines of specific organs.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2000 (estimated)
- First submitted
- 20 Apr 2021
- Start date
- 27 Sept 2019
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Richmond Research Institute
- Diseases
- Obesity, Fatty liver disease (MASLD/MASH)
- NCT number
- NCT04873258
What you commit to
- Study type: Observational
- Planned participants: 2000
- From 27 Sept 2019 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any other significant previous liver pathology (liver malignancy, portal hypertension, infiltrative liver disease)
Other illness
- Known alcoholic liver disease, history of cirrhosis of any other cause (metabolic, viral hepatitis or other)
- An Implanted cardiac devices
Other
- Alcohol consumption \>30 units per week
Who the study is looking for
- Male or female volunteers aged ≥18 to ≤80 years at the date of signing the informed consent.
- Willingness and ability to provide written, personally signed, and dated informed consent, in accordance with the latest ICH Good Clinical Practice (GCP) Guidelines and applicable regulations.
- An understanding, ability and willingness to fully comply with project procedures and restrictions.
- For PART B only:
- 1\. With a known history of MASLD as evidenced either of:
- GP diagnosis on HCF
- Documented Fibroscan or liver US demonstrating MASLD
Age in the registry: 18 years to 80 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Richmond Pharmacology Ltd. 1a Newcomen St, London Bridge Coordinator of this site? Confirm its status | London | United Kingdom | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.